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Summary
Each year, the American Heart Association (AHA), in con-
junction with the Centers for Disease Control and Prevention, 
the National Institutes of Health, and other government agen-
cies, brings together the most up-to-date statistics related to 
heart disease, stroke, and other cardiovascular and metabolic 
diseases and presents them in its Heart Disease and Stroke 
Statistical Update. The Statistical Update represents a criti-
cal resource for the lay public, policy makers, media profes-
sionals, clinicians, healthcare administrators, researchers, and 
others seeking the best available data on these conditions. 
Together, cardiovascular disease (CVD) and stroke produce 
immense health and economic burdens in the United States 
and globally. The Statistical Update brings together in a single 
document up-to-date information on the core health behaviors 
(including diet, physical activity [PA], smoking, and energy 
balance) and health factors (including blood pressure, choles-
terol, and glucose) that define cardiovascular health; a range 
of major clinical disease conditions (including stroke, con-
genital heart disease, rhythm disorders, subclinical atheroscle-
rosis, coronary heart disease, heart failure, valvular disease, 
and peripheral arterial disease); and the associated outcomes 
(including quality of care, procedures, and economic costs). 
Since 2006, the annual versions of the Statistical Update have 
been cited >28 000 times in the literature. In 2014 alone, the 
various Statistical Updates were cited >5000 times.
Each annual version of the Statistical Update undergoes 
major revisions to include the newest nationally representa-
tive data, add additional relevant published scientific findings, 
remove older information, add new sections or chapters, and 
increase the number of ways to access and use the assembled 
information. This year-long process, which begins as soon as 
the previous Statistical Update is published, is performed by 
the AHA Statistics Committee faculty volunteers and staff. For 
example, this year’s edition includes new data on the monitor-
ing and benefits of cardiovascular health in the population, new 
metrics to assess and monitor healthy diets, additional infor-
mation in many chapters on the global CVD and stroke burden, 
new information on stroke in young adults, a new focus on 
underserved and minority populations, and further evidence-
based approaches to changing behaviors, implementation 
strategies, and implications of the AHA’s 2020 Impact Goals. 
Below are a few highlights from this year’s Update.
Current Status of Cardiovascular Health in the 
United States (Chapter 2)
●● The concept of cardiovascular health represents a 
heightened focus for the AHA, with 3 central and novel 
emphases:
—An expanded focus on not only CVD prevention but also 
promotion of positive cardiovascular health, in addition 
to the treatment of established CVD
—The prioritization of both health behaviors (healthy diet 
pattern, appropriate energy balance, PA, and nonsmok-
ing) and health factors (optimal blood lipids, blood pres-
sure, glucose levels) throughout the lifespan as primary 
goals unto themselves
—Population-level health promotion strategies to shift 
the majority of the public toward greater cardiovascu-
lar health, in addition to targeting those individuals at 
greatest CVD risk, because CVD occurs at all risk levels 
across the population and because healthy lifestyles are 
uncommon throughout the US population
●● Among children, the prevalence of ideal levels of cardio-
vascular health behaviors and factors currently varies from 
<1% for the healthy diet pattern to >80% for the smoking, 
blood pressure, and fasting glucose metrics.
●● Among US adults, the prevalence of ideal levels of cardio-
vascular health behaviors and factors currently varies from 
about 1.5% for the healthy diet pattern to up to 78% for the 
smoking metric (never having smoked or being a former 
smoker who has quit for >12 months).
●● Fewer children over time are meeting the ideal body mass 
index metric, whereas more are meeting the ideal smoking 
and total cholesterol metrics. Other metrics do not show 
consistent trends over time in children.
●● More adults over time are meeting the smoking metric, whereas 
fewer are meeting the body mass index and glucose metrics. 
Trends for other metrics are not evident over time in adults.
Effective Approaches to Improve Cardiovascular 
Health (Chapter 2)
●● The current evidence supports a range of complementary 
strategies to improve cardiovascular health, including the 
following:
—Individual-focused approaches, which target lifestyle 
and treatments at the individual level
—Healthcare systems approaches, which encourage, facil-
itate, and reward efforts by providers and patients to 
improve health behaviors and health factors
—Population approaches, which target lifestyle and treat-
ments in schools or workplaces, local communities, and 
states, as well as throughout the nation
●● Such approaches can focus on both (1) improving cardio-
vascular health among those who currently have less than 
optimal levels and (2) preserving cardiovascular health 
among those who currently have ideal levels (in particular, 
children, adolescents, and young adults) as they age.
●● The metrics with the greatest potential for improvement 
are health behaviors, including diet quality, PA, and body 
weight. However, each of the cardiovascular health metrics 
can be improved and deserves major focus.
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Health Behaviors (Chapters 3 to 6)
Based on comparable risk assessment methods, poor lifestyle 
behaviors and lifestyle-related risk factors are the foremost causes 
of death and disability in the United States and in the world.
Smoking/Tobacco Use (Chapter 3)
●● Although tobacco use has declined substantially in the 
United States, it remains the second-leading cause of total 
deaths and disability. The percentage of adults who reported 
current cigarette use declined from 24.1% in 1998 to 16.9% 
in 2014; among high school students, the decline was from 
36.4% in 1997 to 5.6% in 2013. Still, almost one third of 
coronary heart disease deaths are attributable to smoking 
and exposure to secondhand smoke.
●● Declines in tobacco usage in the United States may be threat-
ened by the >450 e-cigarette products that were available in 
2014. To date, the risks and benefits of e-tobacco products 
remain controversial but are an area of intense investiga-
tion by scientists, as well as scrutiny by the US Food and 
Drug Administration. Public health experts are concerned 
that although e-cigarettes are thought to have a lower risk 
of harmful effects than conventional cigarettes, they may be 
a gateway to smoking traditional cigarettes or may promote 
relapse among former smokers, which could erode gains in 
the public’s awareness of the harms of tobacco products.
●● Cigarette smoking is associated with 9% of annual aggre-
gated healthcare spending in the United States. Annual 
smoking-attributable economic costs in the United States, 
including direct medical costs and lost productivity, are 
estimated to exceed $289 billion.
Physical Inactivity (Chapter 4)
●● In 2013, 15.2% of adolescents reported being inactive dur-
ing the prior week, and inactivity was more likely to be 
reported by girls (19.2%) than boys (11.2%). Inactivity was 
more commonly reported by black (27.3%) and Hispanic 
(20.3%) girls than their white counterparts (16.1%); simi-
larly, black (15.2%) and Hispanic (12.1%) boys reported 
more inactivity than white boys (9.2%).
●● According to 2014 National Health Interview Survey data, 
only half of American adults met the current aerobic PA 
guidelines (≥150 minutes of moderate PA or 75 minutes 
of vigorous PA or an equivalent combination each week). 
Women (47.0%) were less likely to meet the guidelines 
than men (53.2%), and non-Hispanic blacks (43.5%) and 
Hispanics (41.3%) were less likely to meet them than non-
Hispanic whites (53.5%).
●● Unfortunately, the proportion of individuals meeting PA 
recommendations is likely to be lower than indicated by 
self-report data. Studies examining actual (with accelerom-
eters, pedometers, etc) versus self-reported PA indicate that 
both men and women overestimate their PA substantially 
(by 44% and 138% for men and women, respectively).
Nutrition (Chapter 5)
●● The leading risk factor for death and disability in the United 
States is suboptimal diet quality, which in 2010 led to 678 000 
annual deaths attributable to all causes. Major contributors 
were insufficient intakes of fruits, nuts/seeds, whole grains, 
vegetables, and seafood, as well as excess intakes of sodium. 
In the United States, an estimated 58 000 annual CVD deaths 
in 2010 were attributable to sodium intake >2.0 g/d, represent-
ing 1 in 16 (6.3%) of all CVD deaths and 1 in 8 (13.1%) CVD 
deaths before age 70 years. Globally, an estimated 1.65 million 
annual CVD deaths were attributable to sodium intake >2.0 
g/d, representing nearly 1 in 10 (9.5%) of all CVD deaths.
●● Between 2003 and 2012, certain aspects of diet quality 
improved in the United States, including increases in whole 
grains and reductions in sugar-sweetened beverages. The prev-
alence of both children and adults meeting the dietary goals 
improved between 2003 to 2004 and 2011 to 2012. The preva-
lence of ideal levels of diet (healthy diet score >80) increased 
from 0.2% to 0.6% in children and from 0.7% to 1.5% in 
adults. During this period, the proportion of youths aged 5 to 
19 years with poor scores on the dietary metric for cardio-
vascular health decreased steadily from 69.2% to 54.6%, 
whereas for adults, the decrease was from 50.3% to 41.0%.
●● Although healthier diets cost modestly more than unhealth-
ful diets, comparing extremes of unhealthful versus health-
ful food-based diet patterns, the more healthful patterns 
cost on average ≈$1.50 per day more. Similarly priced 
options are also common; in a comparison of 20 fruits and 
vegetables versus 20 common snack foods such as cookies, 
chips, pastries, and crackers, the average price per portion 
of fruits and vegetables was 31 cents, with an average of 57 
calories per portion, versus 33 cents and 183 calories per 
portion for snack foods.
Obesity (Chapter 6)
●● Although the overall prevalence of obesity in US youth did 
not change between 2003 to 2004 and 2011 to 2012, the 
prevalence decreased among those aged 2 to 5 years. Obe-
sity decreased among those of higher socioeconomic status 
but increased among those of lower socioeconomic status. In 
addition, the overall prevalence of severe obesity in US youth 
continued to increase, especially among adolescent boys.
●● Overweight and obesity predispose individuals to most 
major risk factors, including physical inactivity, hyperten-
sion, hyperlipidemia, and diabetes mellitus.
●● Excess body weight is among the leading causes of death 
and disability in the United States and globally, with bur-
dens expected to increase in coming years.
●● Among overweight and obese individuals, existing cardio-
metabolic risk factors should be monitored and treated inten-
sively with diet quality, PA, and pharmacological or other 
treatments as necessary. Each of these interventions provides 
benefits independent of weight loss and maintenance.
●● Estimated mean annual per capita healthcare expenses 
attributable to obesity are $1160 for men and $1525 for 
women.
Health Factors (Chapters 7 to 12)
The prevalence and control of cardiovascular health factors 
remains a major issue for many Americans.
Family History and Genetics (Chapter 7)
●● Familial aggregation of CVD is related to clustering of 
specific lifestyle and other risk factors, each of which 
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has environmental and genetic contributors. Patients with 
a family history of coronary artery disease have a higher 
prevalence of traditional CVD risk factors, underscoring 
opportunities for prevention.
●● The risk of most CVD conditions is higher in the presence of a 
family history, including CVD (45% higher odds with sibling 
history), stroke (50% higher odds with history in a first-degree 
relative), atrial fibrillation (AF; 80% higher odds with parental 
history), heart failure (70% higher odds with parental history), 
and peripheral arterial disease (80% higher odds with fam-
ily history). This excess risk reflects genetic, epigenetic, and 
shared behavioral and environmental risk factors.
High Blood Cholesterol and Other Lipids (Chapter 8)
●● 75.7% of children and 46.6% of adults have ideal choles-
terol levels (untreated total cholesterol <170 mg/dL for 
children and <200 mg/dL for adults). Prevalence of ideal 
levels has improved over the past decade in children but 
remained the same in adults.
●● According to 2009 to 2012 data, >100 million US adults 
≥20 years of age have total cholesterol levels ≥200 mg/dL; 
almost 31 million have levels ≥240 mg/dL.
●● During 2003 to 2012, the percentage of adults aged ≥40 
years who had used a cholesterol-lowering medication in 
the past 30 days increased from 20% to 28%.
High Blood Pressure (Chapter 9)
●● Based on 2009 to 2012 data, 32.6% of US adults ≥20 years 
of age have hypertension, which represents ≈80.0 million 
US adults. African American adults have among the highest 
prevalence of hypertension in the world. Among non-His-
panic black men and women, the age-adjusted prevalence 
of hypertension was 44.9% and 46.1%, respectively.
●● National Health and Nutrition Examination Survey 
(NHANES) data from 2009 to 2012 revealed that among 
US adults with hypertension, 54.1% were controlled, 
76.5% were currently treated, 82.7% were aware they had 
hypertension, and 17.3% were undiagnosed.
●● From 2003 to 2013, the death rate attributable to high blood 
pressure increased 8.2%, and the actual number of deaths 
rose 34.7% (National Heart, Lung, and Blood Institute 
tabulation). During this 10-year period, the corresponding 
values were a 14.4% and 30.9% increase in non-Hispanic 
whites; a 1.7% and 75.5% increase in Hispanics; and a 
9.1% decrease and 18.4% increase in non-Hispanic blacks.
Diabetes Mellitus (Chapter 10)
●● Diabetes mellitus affects 1 in 10 US adults, with 90% to 
95% of cases being type 2 diabetes mellitus. Diabetes melli-
tus disproportionately affects racial/ethnic minorities. Type 
2 diabetes mellitus is increasingly common in children and 
adolescents; the disease historically was diagnosed primar-
ily in adults ≥40 years of age. The prevalence of type 2 
diabetes mellitus in children/adolescents has increased 
by 30.5% between 2001 and 2009, and it now constitutes 
≈50% of all childhood diabetes mellitus.
●● Diabetes mellitus is associated with reduced longevity; 
men and women with diabetes mellitus live an average of 
7.5 and 8.2 years less, respectively, than their counterparts 
without diabetes mellitus.
Metabolic Syndrome (Chapter 11)
●● From 1999 to 2010, the age-adjusted national prevalence of 
metabolic syndrome in the United States peaked (in 2001–
2002) and began to fall. This is attributable to decreases in 
the age-adjusted prevalence among women and no change 
in men. In addition, there has been variation in the trends 
over time for each individual component of the metabolic 
syndrome. Generally, the national prevalences of hypertri-
glyceridemia and elevated blood pressure have decreased, 
whereas hyperglycemia and elevated waist circumference 
have increased. However, these trends also vary signifi-
cantly by sex and race/ethnicity.
●● Perhaps most importantly with respect to meeting the 2020 
goals, the prevalence of metabolic syndrome increases 
with greater cumulative life-course exposure to sedentary 
behavior and physical inactivity; screen time, including 
television viewing; fast food intake; short sleep duration; 
and intake of sugar-sweetened beverages. Each of these 
risk factors is reversible with lifestyle change.
Cardiovascular Conditions/Diseases (Chapters 13 
to 22)
Rates of death attributable to CVD have declined in the United 
States, but the burden remains high.
Total Cardiovascular Diseases (Chapter 13)
●● The 2013 overall rate of death attributable to CVD was 
222.9 per 100 000 Americans. The death rates were 269.8 
for males and 184.8 for females. The rates were 270.6 for 
non-Hispanic white males, 356.7 for non-Hispanic black 
males, 197.4 for Hispanic males, 183.8 for non-Hispanic 
white females, 246.6 for non-Hispanic black females, and 
136.4 for Hispanic females.
●● From 2003 to 2013, death rates attributable to CVD declined 
28.8%. In the same 10-year period, the actual number of 
CVD deaths per year declined by 11.7%. Yet in 2013, CVD 
still accounted for 30.8% (800 937) of all 2 596 993 deaths, 
or ≈1 of every 3 deaths in the United States.
●● On the basis of 2013 death rate data, >2200 Americans die 
of CVD each day, an average of 1 death every 40 seconds. 
Approximately 155 000 Americans who died of CVD in 
2013 were <65 years of age. In 2013, 35% of deaths attrib-
utable to CVD occurred before the age of 75 years, which 
is younger than the current average life expectancy of 78.8 
years.
●● For the first time since 1983, more males (402 851) died of 
CVD than females (398 086).
Stroke (Chapter 14)
●● In 2013, stroke fell from the fourth to the fifth leading cause 
of death in the United States, behind diseases of the heart, 
cancer, chronic lower respiratory diseases, and uninten-
tional injury.
●● From 2003 to 2013, the relative rate of stroke death fell 
by 33.7% and the actual number of stroke deaths declined 
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by 18.2%. Yet each year, ≈795 000 people continue to 
experience a new or recurrent stroke (ischemic or hem-
orrhagic). Approximately 610 000 of these are first events 
and 185 000 are recurrent stroke events. In 2013, stroke 
caused ≈1 of every 20 deaths in the United States. On aver-
age, every 40 seconds, someone in the United States has 
a stroke, and someone dies of one approximately every 4 
minutes.
●● The decline in stroke mortality over the past decades, a 
major improvement in population health observed for 
both sexes and all race and age groups, has resulted from 
reduced stroke incidence and lower case fatality rates. The 
significant improvements in stroke outcomes are concur-
rent with cardiovascular risk factor control interventions. 
The hypertension control efforts initiated in the 1970s 
appear to have had the most substantial influence on the 
accelerated decline in stroke mortality, with lower blood 
pressure distributions in the population. Control of diabe-
tes mellitus and high cholesterol and smoking cessation 
programs, particularly in combination with hypertension 
treatment, also appear to have contributed to the decline in 
stroke mortality.
●● Approximately 10% of all strokes occur in people 18 to 
50 years of age. Between 1995 and 2008, National Health 
Interview Survey data reveal that hospitalizations for 
ischemic stroke increased among adolescents and young 
adults (aged 5–44 years), whereas subarachnoid hemor-
rhage hospitalizations decreased during that same time 
period.
●● Stroke death rates declined more among people aged ≥65 
years (−54.1%; from 534.1 to 245.2 per 100 000) than 
among those aged 45 to 64 years (−53.6%; from 43.5 to 
20.2 per 100 000) or those aged 18 to 44 years (−45.9%; 
from 3.7 to 2.0 per 100 000).
Atrial Fibrillation (Chapter 16)
●● Multiple lines of evidence have increased awareness of the 
burden of unrecognized AF. In individuals without a his-
tory of AF with recent pacemaker or defibrillator implan-
tation, subclinical atrial tachyarrhythmias were detected 
in 10.1% of patients. Subclinical atrial tachyarrhythmias 
were associated with a 5.6-fold higher risk of clinical 
AF and ≈13% of ischemic strokes or embolism. A recent 
systematic review suggested that one needs to screen 170 
community-based individuals at least 65 years of age to 
detect 1 case of AF.
●● In the Framingham Heart Study, there have been striking 
temporal trends in the epidemiology of AF documented 
over 50 years. The age-adjusted incidence and prevalence 
of AF in the white participants increased ≈4-fold, yet the 
multivariable adjusted hazard of stroke (74%) and death 
(25%) associated with AF declined over the same time 
period. Less is known about the epidemiology of AF over 
time in ethnic/racial minorities.
●● Secondary analyses of observational and randomized data 
generally support benefits of risk factor modification for 
primary prevention of AF. There is also growing evidence 
supporting the value of risk factor reduction, particularly 
weight management and exercise, in secondary prevention 
of AF recurrences and symptoms.
Sudden Cardiac Arrest (Chapter 17)
●● Each year ≈359 800 people experienced emergency medi-
cal services–assessed out-of-hospital cardiac arrests in the 
United States. Survival to hospital discharge after nontrau-
matic emergency medical services–treated cardiac arrest 
with any first recorded rhythm was 10.6% for patients of 
any age. Of the ≈20 150 bystander-witnessed out-of-hos-
pital cardiac arrests in 2011, 31.4% of victims survived to 
hospital discharge.
●● Each year, ≈209 000 people are treated for in-hospital car-
diac arrest.
Subclinical Atherosclerosis (Chapter 18) and Coronary 
Heart Disease (Chapter 19)
●● CAC was noted as highly predictive of CHD event risk 
across all age groups, suggesting that once CAC is known, 
chronological age has less importance. Compared with a 
CAC score of 0, CAC >100 imparted an increased mul-
tivariable-adjusted CHD event risk in younger individuals 
(45-54 years old) with an HR of 12.4. The respective risk 
was similar even in the very elderly (75-84 years of age) 
with an HR of 12.1.
●● Coronary heart disease alone caused ≈1 of every 7 deaths 
in the United States in 2013. In 2013, 370 213 Americans 
died of coronary heart disease. Each year, an estimated 
≈660 000 Americans have a new coronary attack (defined 
as first hospitalized myocardial infarction or coronary heart 
disease death) and ≈305 000 have a recurrent attack. It 
is estimated that an additional 160 000 silent myocardial 
infarctions occur each year. Approximately every 34 sec-
onds, 1 American has a coronary event, and approximately 
every 1 minute 24 seconds, an American will die of one.
Heart Failure (Chapter 20)
●● In 2013, 1 in 9 death certificates (284 388 deaths) in the 
United States mentioned heart failure. Heart failure was 
the underlying cause in 58 309 of those deaths. The num-
ber of any-mention deaths attributable to heart failure was 
approximately as high in 1995 (287 000) as it was in 2013 
(284 000). Additionally, hospital discharges for heart fail-
ure remained stable from 2000 to 2010, with first-listed dis-
charges of 1 008 000 and 1 023 000, respectively.
●● Mortality declines in heart failure have been documented, 
likely related to evidence-based approaches to treat heart 
failure risk factors and to implementation of angiotensin-
converting enzyme inhibitors, β-blockers, coronary revas-
cularization, implantable cardioverter-defibrillators, and 
cardiac resynchronization therapeutic strategies.
Valvular, Venous, and Aortic Diseases (Chapter 21) and 
Peripheral Artery Disease (Chapter 22)
●● Data suggest that the prevalence of any valve disease is 
2.5%, with no difference between men and women.
●● In 2013, 50 222 deaths were related to valvular HD. Of 
those, 67.5% were due to aortic valve disorders.
●● PAD affects ≈8.5 million Americans aged ≥40 years and is 
associated with significant morbidity and mortality.
●● In 2013, PAD any-mention mortality was 61 097. PAD was 
the underlying cause in 13 639 of those deaths.
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●● The risk factors for PAD are similar but not identical to 
those for CHD. DM and cigarette smoking are stronger risk 
factors for PAD than for CHD. Most studies suggest that 
the prevalence of PAD is similar in men and women. Meta-
bolic syndrome in older persons (driven most prominently 
by the HBP component) and elevated inflammation mark-
ers are also risk factors.
Cardiovascular Quality of Care, Procedure 
Utilization, and Costs (Chapters 23 to 25)
The Statistical Update provides critical data in several sec-
tions on the magnitude of healthcare delivery and costs, as 
well as the quality of healthcare delivery, related to CVD risk 
factors and conditions.
Quality-of-Care Metrics for CVD (Chapter 23)
●● The Institute of Medicine has identified 6 domains of qual-
ity of care, including safety, effectiveness, patient-centered 
care, timely care, efficiency, and equitable care.
●● According to the Medicare Patient Safety Monitoring Sys-
tem, between 2005 and 2011, adverse event rates in hos-
pitalized patients declined for both myocardial infarction 
(from 5.0% to 3.7%) and congestive heart failure (from 
3.7% to 2.7%)
●● However, in the Practice Innovation and Clinical Excel-
lence (PINNACLE) outpatient registry, only 66.5% of 
eligible patients with coronary artery disease received the 
optimal evidence-based combination of medications.
●● A randomized trial of post–acute coronary care syndrome 
that used multiple modalities to enhance adherence to 4 
indicated medications (clopidogrel, statins, angiotensin-
converting enzyme inhibitors/angiotensin receptor block-
ers, and β-blockers) demonstrated better adherence in the 
intervention group (89.3% versus 73.9%) at 1 year.
●● A recent study from a Veterans Health Administration 
national cohort of CVD patients showed that women with 
CVD were less likely than men to receive statins (57.6% 
versus 64.8%) or high-intensity statins (21.1% versus 
23.6%) as recommended in the 2013 American College of 
Cardiology/AHA cholesterol management guidelines. The 
authors concluded that although women with CVD are less 
likely to receive evidence-based statin and high-intensity 
statins than men, their use remains low in both sexes.
●● Similar or larger challenges persist in the outpatient setting 
in discussion and counseling for PA and dietary habits.
Cardiovascular Procedure Use and Costs (Chapters 24 and 25)
●● The total number of inpatient cardiovascular operations and 
procedures increased 28% between 2000 and 2010, from 
5 939 000 to 7 588 000.
●● Data on Medicare beneficiaries undergoing a coronary 
revascularization procedure between 2008 and 2012 indi-
cate that the rapid growth in nonadmission percutaneous 
coronary interventions (from 60 405 to 106 495) has been 
more than offset by the decrease in percutaneous coronary 
intervention admissions (from 363 384 to 295 434).
●● According to the 2012 National Healthcare Cost and Utili-
zation Project statistics, the mean hospital charge for a vas-
cular or cardiac surgery or procedure in 2012 was $78 897: 
cardiac revascularization cost $149 480, and percutaneous 
interventions cost ≈$70 027.
●● For 2011 to 2012, the estimated annual costs for CVD and 
stroke were $316.6 billion, including $193.1 billion in 
direct costs (hospital services, physicians and other pro-
fessionals, prescribed medications, home health care, and 
other medical durables) and $123.5 billion in indirect costs 
from lost future productivity (cardiovascular and stroke 
premature deaths). CVD costs more than any other diag-
nostic group.
●● By comparison, in 2011, the estimated direct cost of all 
cancer was $88.7 billion (50% for outpatient or doctor 
office visits, 35% for inpatient care, and 11% for prescrip-
tion drugs).
Conclusions
The AHA, through its Statistics Committee, continuously 
monitors and evaluates sources of data on heart disease and 
stroke in the United States to provide the most current infor-
mation available in the Statistical Update. This annual Sta-
tistical Update is the product of a full year’s worth of effort 
by dedicated volunteer physicians and scientists, committed 
government professionals, and outstanding AHA staff mem-
bers, without whom publication of this valuable resource 
would be impossible. Their contributions are gratefully 
acknowledged.
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